Skip to main content
Smart Investors Daily
AV

NASDAQ · AVR

Anteris Technologies Global Corp.

Healthcare · Medical - Devices

$5.09

Down-$0.12 (-2.30%)

Updated Nov 20, 2026, 2:05 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
172.44M
P/E ratio
-1.47
Dividend yield
0.00%
52-week range
$3.30 – $11.06
Volume
1.26M
Avg. volume
248.1K

Price performance · AVR

AVR price history

1M range · 0 trading sessions · Daily adjusted prices

AVR does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AVR news

The latest Smart Investors Daily articles mentioning AVR.

AVR research

Overview

Company profile and research snapshot.

Company profile

Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
AVR recent ratings
DateFirmRatingTarget
Nov 13, 2026BarclaysEqual-Weight—
Oct 14, 2026Cantor FitzgeraldOverweight—
Oct 7, 2026BarclaysEqual-Weight—
Aug 14, 2026Cantor FitzgeraldOverweight—
May 15, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 16, 2026

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients

MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom. The presentation will report one-year clinical and hemodynamic outcomes fro

Yahoo · Nov 10, 2026

Anteris Technologies Announces Results for the Third Quarter of 2026

MINNEAPOLIS and BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2026, and provided a corporate update. Q3 2026 Highlights Continued execution of the PARADIGM Trial, with enrollment progres

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.